8.3 Blood Labeling and Administration Techniques

8.3 Blood Labeling and Administration Techniques

Quick Answer: RBCs are labeled in vivo, modified in vivo, or in vitro (UltraTag®) for MUGA and GI bleeding. WBCs are labeled with In-111 oxine or Tc-99m HMPAO for infection imaging. Always calculate labeling efficiency, use aseptic technique, and perform two-identifier patient/sample checks before reinjection.

Wrong-patient cell reinjection is a never-event. Exam stems hide ID failures, free Tc after poor RBC labels, or low WBC efficiency.

RBC Labeling Methods

Goal: bind Tc-99m to hemoglobin so activity stays in the blood pool. Stannous ion (Sn²⁺) pretinning reduces technetium for intracellular binding. Inadequate tin or oxidizing interference leaves free pertechnetate in stomach, thyroid, and salivary glands.

Interfering factors: recent transfusion, residual line heparin, oxidizing drugs, wrong kit order, or short incubation. Do not inject pertechnetate before tin in pure in vivo labeling. Uses: MUGA/ERNA, GI bleeding, hemangioma blood-pool—typical adult activity often ~20–30 mCi when well labeled.

WBC Labeling: In-111 Oxine and Tc-99m HMPAO

Labeled leukocytes localize at sites of infection/inflammation (sterile inflammation can still light up—specificity has limits). Maintain closed sterile technique throughout; cell damage from rough handling lowers both viability and labeling efficiency.

Shared Workflow Principles

1. Verify identity of patient and collection tubes before phlebotomy.
2. Draw adequate venous blood into anticoagulant (ACD or heparin per protocol).
3. Sediment / centrifuge to separate leukocyte-rich fraction; remove RBCs as required.
4. Incubate cells with lipophilic chelate (In-111 oxine or Tc-99m exametazime/HMPAO).
5. Wash to remove unbound activity; assay bound vs free.
6. Resuspend and reinject IV only into the same patient after dual ID check.
7. Image at agent-appropriate times (In-111 often 4–24 h; Tc-99m HMPAO earlier windows).

Low efficiency → free activity artifacts and poor contrast. Plasma proteins compete with oxine—washing technique matters. Neutropenia may yield inadequate cells; process one patient at a time on the bench.

Labeling Efficiency Calculation

$$\text{Labeling efficiency (\%)} = \frac{\text{Activity in cells (bound)}}{\text{Activity in cells} + \text{Activity in supernatant (free)}} \times 100$$

Assay both fractions in a dose calibrator (geometry per SOP). Document efficiency before injection. Below the departmental limit → do not reinject without authorized radiopharmacy/user disposition (relabel or reschedule). Example: cells 9.2 mCi, supernatant 0.8 mCi → 9.2/10.0 × 100% = 92%.

Routes of Administration

Route errors are high-severity: an oral therapy capsule is not an IV push, and a filtered colloid lymph dose is not a liver-spleen IV dose. Always read the order, label, and written directive together before the needle or capsule reaches the patient.

Bolus for rapid first-pass or fixed regadenoson timing; infusion for adenosine, dipyridamole, dobutamine, amino acids—use controlled delivery and stay with the patient. Asepsis: scrub hubs, sterile technique for cell labels/intrathecal/therapy; labeled blood is autologous yet still biohazardous and radioactive.

Critical Patient-Sample Identity Checks

Before collection, labeling, and reinjection: (1) two identifiers matched to wristband, requisition, and labels; (2) label tubes/syringes at bedside immediately; (3) worksheet matches name, ID, RP, activity, route, time, and written directive when required; (4) second-person verify therapies/blood products per policy; (5) any mismatch → stop.

Infiltration: stop, mark site, estimate residual, notify authorized user, survey, manage site per isotope policy, and decide if remaining activity meets the study need.

Master the efficiency formula, three RBC methods, WBC step chain, and identity culture—these four themes dominate CNMT administration items more than obscure kit brand names.